Non-Small Cell Lung Cancer

Latest News

Lung cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com
Survival Outcomes in Advanced NSCLC Improved With Use of Cemiplimab

September 10th 2025

The use of cemiplimab with chemotherapy showed durable improvements in survival outcomes for non-small cell lung cancer (NSCLC) after 5 years.

AI gen NSCLC lungs | Image credit: PRASANNAPIX - stock.adobe.com
Cemiplimab Shows 5-Year Survival Benefit in Advanced NSCLC With High PD-L1 Expression

September 8th 2025

Lung cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com
Cancer-Specific Outcomes Improved With Adherence to Quality Metrics

September 3rd 2025

Advances in Oncology: When Innovation and Challenge Intersect
Advances in Oncology: When Innovation and Challenge Intersect

August 21st 2025

For Better Cancer Outcomes, It’s All About Access
For Better Cancer Outcomes, It’s All About Access

August 21st 2025

Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes

Get insight to advances in ALK+ NSCLC treatment, including long-term lorlatinib data, new therapy approvals, brain metastasis management, and evolving sequencing strategies with this series.

AJMC Peer Exchange logo
Continuing Medical Education
View All
September 14th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
September 14th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Shackled with bills | Image Credit: petrovk - stock.adobe.com
April 17th 2024

Financial Strain, Quality of Life Top Unmet Needs in Lung Cancer Survivors

Maggie L. Shaw
The data for this analysis on survivors of lung cancer came from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center thoracic oncology clinics.
Lung cancer in black marker | Image Credit: MPStudio - stock.adobe.com
April 11th 2024

Expert Analysis Reveals Critical Insights for Optimizing Care in LA-NSCLC

Maggie L. Shaw
Authors conducted a systematic literature review to gather evidence on the appropriateness of recommended treatments for locally advanced non–small cell lung cancer (LA-NSCLC) from the American Radium Society Appropriate Use Criteria Thoracic Committee.
Intravenous drip in the pole against the bright light | Image Credit: sudok1 - stock.adobe.com
April 9th 2024

Neoadjuvant Chemoimmunotherapy Shows Superiority in Non–Small Cell Lung Cancer Treatment

Giuliana Grossi
The study compared the adverse events and surgical, pathological, and efficacy outcomes associated with neoadjuvant chemoimmunotherapy vs chemotherapy, particularly focusing on patients with PD-L1 levels less than 1%.
Medical doctor drawing lung cancer on the virtual screen | Image Credit: WrightStudio - stock.adobe.com
April 2nd 2024

Navigating Complexity: Understanding Variations in Lung Cancer Screening Decision-Making

Maggie L. Shaw
This analysis found the complex decision-making process of lung cancer screening among eligible individuals is infused with 3 principal themes that may influence how primary care physicians approach patients with comorbidities.
Wearable tech activity tracker | Image Credit: Orxan - stock.adobe.com
March 28th 2024

Wearable Activity Tracker Data Enhance Patient Assessment in Lung Cancer

Maggie L. Shaw
This analysis included 119 patients with advanced lung cancer, who were evaluated on 3 facets of physical activity over 14 days of using the amuelink wearable device from Sony: metabolic equivalent tasks, distance walked, and steps taken.
Gene expression profiling on blue backgound | Image Credit: dariaren - stock.adobe.com
March 23rd 2024

Experts Sound the Alarm on Lack of Comprehensive Genomic Profiling in NSCLC

Maggie L. Shaw
Investigators examined the downstream effect of single-gene testing for guideline-recommended biomarkers on comprehensive genomic profiling in non–small cell lung cancer (NSCLC).
A lung specialist | Image Credit: mi_viri - srock.adobe.com
March 21st 2024

Low Screening Rates for Lung Cancer Highlight Public Health Priority

Maggie L. Shaw
Overall rates for lung cancer screening remain low, despite the US Preventive Services Task Force revising its annual screening recommendation in 2021 by lowering the age of initial screening for current or former smokers and their pack-year history.
Doctor lung cancer tablet | Image Credit: © steph photographies - stock.adobe.com
March 15th 2024

ctDNA Holds Potential to Guide Management of EGFR-Mutated NSCLC

Christina Mattina
A review explores the evidence supporting the use of circulating tumor DNA (ctDNA) liquid biopsies to help direct the evaluation and management of EGFR-mutated non–small cell lung cancer (NSCLC), including for assessing resistance to certain treatment options.
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
March 14th 2024

Dr Joshua Sabari Looks to the Future of Targeted Treatment for NSCLC

Maggie L. Shaw
March 1 saw the FDA grant full approval to amivantamab plus chemotherapy for first-line use in patients who have non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, converting the May 2021 accelerated approval for this treatment in the second line.
Women undergoing radiation for cancer | Image Credit: My Ocean studio - stock.adobe.com
March 12th 2024

SABR Likely Safe, Effective for Patients Who Have NSCLC, ILD

Maggie L. Shaw
In this study, the 42-patient population was enrolled from 5 sites in Canada and 1 site in Scotland, and data were gathered from March 7, 2019, to January 12, 2022; all had interstitial lung disease (ILD) and early-stage non–small cell lung cancer (NSCLC).
Joshua K. Sabari, MD< NYU Langone Perlmutter Cancer Center
March 4th 2024

Dr Joshua Sabari Discusses Amivantamab’s First-Line Approval for NSCLC

Maggie L. Shaw
The approval converts the May 2021 accelerated FDA approval for second-line treatment of non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations to a full approval in the first line following results from the phase 3 PAPILLON study.
Lung cancer science and technology | Image credit: sergey nivens - stock.adobe.com
February 29th 2024

Robotic Lobectomy Techniques Yield Comparable Outcomes in NSCLC

Maggie L. Shaw
Investigators were searching for answers to the question, “Does it matter if a vein- or artery-first approach is used when performing a robotic lobectomy for non-small cell lung cancer (NSCLC)?
Nivolumab | Image credit: luchschenF - stock.adobe.com
February 27th 2024

Nivolumab Continues to Produce Beneficial NSCLC Outcomes

Maggie L. Shaw
This most recent analysis from the CheckMate 9LA trial provides 4-year follow-up data on patients with stage IV metastatic/recurrent non–small cell lung cancer (NSCLC) randomized to treatment with nivolumab plus ipilimumab and chemotherapy vs chemotherapy alone.
FDA logo on gray paper | Image credit: Araki Illustrations - stock.adobe.com
February 19th 2024

FDA Accepts BLA for Datopotamab Deruxtecan for Nonsquamous NSCLC

Laura Joszt, MA
The application is based on results of the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan in nonsquamous non–small cell lung cancer (NSCLC), first presented at the 2023 European Society for Medical Oncology Congress.
FDA logo | Image: FDA
February 19th 2024

Osimertinib With Chemo Gains FDA Approval for EGFR-Mutated NSCLC

Mary Caffrey
Besides the new approval, AstraZeneca released preliminary results for LAURA evaluating osimertinib after chemoradiotherapy.
Tennessee Oncology’s Brandes Sees Progress in Biomarker Use in NSCLC, but “There’s Work to Be Done”
February 15th 2024

Tennessee Oncology’s Brandes Sees Progress in Biomarker Use in NSCLC, but “There’s Work to Be Done”

Mary Caffrey
Coverage of Tennessee Oncology's Johann Brandes, MD, on "Precision Medicine in NSCLC."
Abstrat image of lung cancer | Image credit: Tex Vector - stock.adobe.com
February 12th 2024

Durvalumab Consolidation Therapy Shows Promise in Elderly Patients With Stage III NSCLC

Maggie L. Shaw
Consolidation durvalumab led to comparable outcomes among older patients with unresectable stage III non–small cell lung cancer (NSCLC) vs a younger cohort with the same cancer; this patient population was underrepresented in the PACIFIC trial.
Biomarkers DNA Biology Evidence Word 3d Render Illustration | Image credit: iQoncept - Adobe Stock
February 9th 2024

In-House Biomarker Testing Shortens Time to Treatment Decision for mNSCLC

Maggie L. Shaw
This retrospective analysis compared molecular testing outcomes among newly diagnosed cases of metastatic non–small cell lung cancer (mNSCLC) from 2 periods: March 2017 to May 2019 and July 2019 to March 2021.
Dr Mark Socinski
February 7th 2024

Dr Mark Socinski on the Need for Lung Cancer Screening in Eligible Patients

Rose McNulty
Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discusses the importance of lung cancer screening in eligible patients, including the need for primary care providers to ensure screening is being implemented.
Inflamed lungs | Image credit: SciePro - stock.adobe.com
January 30th 2024

Pneumonitis Risk in NSCLC Remains Uncertain, Obesity May Be Predictor

Maggie L. Shaw
Outcomes were evaluated among veterans treated for non–small cell lung cancer (NSCLC) from 2017 to 2020 with durvalumab, a PD-L1 inhibitor.
Dr Melinda Aldrich - Vanderbilt University Medical Center
January 25th 2024

Dr Melinda Aldrich on Disparities and the Importance of Screening in Lung Cancer

Hayden E. Klein Rose McNulty
Melinda Aldrich, PhD, MHE, associate professor in the Vanderbilt University School of Medicine in the division of genetic medicine, discussed her ongoing research aiming to identify the drivers of disparities in lung cancer outcomes in the US.
Gilead headquarters in Silicon Valley | Image Credit: Sundry Photography - stock.adobe.com
January 23rd 2024

Sacituzumab Govitecan Monotherapy for NSCLC Disappoints in EVOKE-01 Trial Update

Maggie L. Shaw
The TROP-2–directed antibody drug conjugate is currently being investigated as a monotherapy and a combination therapy for non–small cell lung cancer (NSCLC) in 3 trials: phase 3 EVOKE-01, phase 2 EVOKE-02, and phase 3 EVOKE-03.
Molly Mendenhall
January 18th 2024

Molly Mendenhall on Standardizing Comprehensive Biomarker Testing in NSCLC

Pearl Steinzor Rose McNulty
Molly Mendenhall, BSN, RN, director of quality and compliance at Oncology Hematology Care, Inc (OHC), discussed a 1-year quality improvement project implemented by OHC to standardize comprehensive biomarker testing in patients with non–small cell lung cancer (NSCLC).
AFFORDABLE CARE ACT | Image credit: Atstock Productions-stock.adobe.com
January 16th 2024

NSCLC-Related Mortality Improves in Medicaid Expansion States

Maggie L. Shaw
This new study examined postoperative survival among discharged patients following treatment of non–small cell lung cancer (NSCLC) via surgical resection using the National Cancer Database.
Michael Gieske, MD, St. Elizabeth Health Care
January 12th 2024

Dr Michael Gieske on Successes and Challenges in Increasing Lung Cancer Screening in Rural Regions

Pearl Steinzor Rose McNulty
Michael Gieske, MD, director of lung cancer screening at St. Elizabeth Health Care, speaks to the success of the Rural Appalachian Lung Cancer Screening Initiative, along with challenges to implementing increased lung cancer screening.
Lung cancer illustration | Image credit: SciePro - stock.adobe.com.jpg
January 12th 2024

Hypofractionated Chemoradiation Regimen With an Adaptive SABR Boost Shows Promise in NSCLC

Rose McNulty
An early-phase, dose-escalation study of a hypofractionated approach to concurrent chemoradiation using an an adaptive stereotactic ablative radiotherapy (SABR) boost showed promising results in patients with locally advanced, unresectable non­­–small cell lung cancer (NSCLC).
Melinda C. Aldrich, PhD, MPH, Vanderbilt University
January 5th 2024

Updated Guidelines Expand Lung Cancer Screening Eligibility for At-Risk Patients: Dr Melinda Aldrich

Hayden E. Klein Rose McNulty
Melinda C. Aldrich, PhD, MPH, associate professor in the departments of medicine, thoracic surgery, and biomedical informatics at Vanderbilt University, discussed recently updated lung screening guidelines from the American Cancer Society and the importance of equity across populations as new guidelines are developed.
Michael Gieske, MD
January 5th 2024

Dr Michael Gieske on Addressing Lung Cancer Screening Disparities in Rural America

Pearl Steinzor Rose McNulty
Michael Gieske, MD, director of lung cancer screening at St. Elizabeth Health Care, discusses disparities in lung cancer incidence and mortality that the Rural Appalachian Lung Cancer Screening Initiative aims to address.
DNA | Image credit: BillionPhotos.com - stock.adobe.com
December 20th 2023

Multigene Testing Helpful in Giving Targeted Treatment in NSCLC

Julia Bonavitacola
Patients with non–small cell lung cancer (NSCLC) who tested positive for driver gene alteration had longer overall survival when given targeted therapy.
Lung cancer treatment and prevention concept | Image credit: Dr_Microbe - stock.adobe.com
December 15th 2023

Frontline Serplulimab Plus Chemo Provides Consistent Survival Benefit in Squamous NSCLC

Courtney Flaherty
The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer.
<123456>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo